Company

Alcedis Expands U.S. Respiratory CRO Capabilities Following Huma’s Acquisition of Aluna

The largest US RPM footprint in respiratory care now supports end-to-end clinical research

 

New York, US — May 26, 2025 — Alcedis Inc., the AI-first clinical research organization (CRO) and part of the Huma Group, today announced a significant expansion of its U.S. respiratory clinical trial capabilities. This milestone follows the acquisition of Aluna, a leading AI-powered remote patient monitoring (RPM) company specializing in respiratory health, by Huma, the global healthcare AI leader.

The acquisition firmly positions Huma as the largest RPM provider in the respiratory space, supporting more than 500,000 contracted lives across hundreds of clinics and health systems in the United States.

In response, Alcedis is launching a dedicated, AI-first U.S. respiratory CRO program, built to support a wide range of clinical trials across multiple therapeutic areas. This includes:

  • Therapeutic Focus Areas: Asthma, COPD, lung cancer, sleep apnea, cystic fibrosis, and other chronic respiratory conditions

  • Proven Track Record: Years of operational excellence delivering complex respiratory trials across global markets

  • End-to-End Research Capabilities: Patient recruitment, site activation, protocol development, digital endpoints, real-world data capture, and regulatory submissions

“Together with Aluna, we have significantly expanded our reach into respiratory research, adding over 150 U.S.-based health systems and clinic networks to our growing global footprint to better power clinical trials,” said Hanno Härtlein, CEO of Alcedis Inc. “This aligns perfectly with our vision of combining AI-powered clinical research with real-world digital health infrastructure.”

Aluna’s platform integrates a portable, FDA-cleared spirometer, an intuitive mobile application, and a clinician portal, enabling real-time lung function tracking and deeper patient engagement from home. Combined with Huma’s AI-powered platform and Alcedis’ CRO expertise, this creates a seamless ecosystem for smarter, faster, and more inclusive respiratory studies.

Alcedis brings more than two decades of respiratory clinical research leadership, including:

  • 34+ respiratory trials conducted

  • 18,000+ patients enrolled

  • 3,200 activated sites across 25 countries

  • Integration of digital biomarkers such as FEV1 (smart spirometry), HRV, oxygen saturation, physical activity, and connected inhalers

This strategic expansion enables the Huma Group to provide a comprehensive, end-to-end solution for respiratory clinical trials—from protocol development through real-world outcome monitoring—positioning the company as a preferred partner for biopharma companies accelerating respiratory drug development and commercialization.

 

 

ABOUT HUMA

Huma is a healthcare AI company that owns and operates leading digital health applications. Its portfolio powers health systems, pharmaceutical companies, and CROs across more than 70 countries, transforming healthcare delivery at scale. Huma’s disease-agnostic cloud platform is designed for rapid, no-code configuration and AI/ML integration, and has been recognized with FDA 510(k) Class II, EU/MDR Class IIb, and other major regulatory certifications. These capabilities enable the company to quickly launch new use cases and optimize acquired assets. Learn more at huma.com.

 

ABOUT ALUNA

Aluna provides an AI-powered remote patient monitoring solution, integrating a portable, FDA-cleared spirometer, an intuitive mobile application, and a clinician portal. This integrated system enables live, real-world tracking of lung function and respiratory health. Developed by UC Berkeley Engineering graduates with firsthand experience of respiratory conditions, Aluna prioritizes user-friendliness and engagement, incorporating interactive features and rewards to encourage consistent use and adherence. Aluna’s provider dashboard allows doctors to remotely access patient data, enhancing telemedicine capabilities and offering valuable health insights. The collection of real-time data in everyday settings allows for the assessment of respiratory medication and therapy effectiveness for individuals affected by asthma, COPD, cystic fibrosis, and other respiratory conditions.

 

ABOUT ALCEDIS

Alcedis is a leading digital- and AI-first CRO with over 30 years of operational experience in over 70 countries. We combine in-depth expertise with state-of-the-art digital solutions, including AI-powered platforms and automated data integration, to efficiently and accurately conduct clinical trials - from Phase I to market authorization and real-world evidence. As a proud member of the Huma Group, we are committed to enabling faster and more efficient research processes by bridging the gap between innovation and practical application in healthcare, driving progress in drug development and patient care forward. Learn more at alcedis.com.